Aurora's functional genomics technology can successfully analyze over half a billion discrete cells derived from 20 million independent GenomeScreen(TM) clones in one day. It's GenomeScreen(TM) technology acts as a search engine to rapidly scan the genome of living, human cells to find genes associated with specified diseases or physiological processes. ABSC has technology capable of searching through expansive libraries of compounds to identify those that might lead to new medicines. This enables Aurora to rapidly identify commercially relevant genes, and to directly develop screens for drug discovery, faster and more efficiently than existing methods. To date, Aurora has filed for patent protection on over 100 previously unknown gene sequences, including their use for compound screening, human diagnostics and dr

ge·nome - set of chromosomes: the full complement of genetic information that an individual organism inherits from its parents, especially the set of chromosomes and the genes they carry.

Disclaimer: (its really good and it took me a lot of time to phrase it just right, so please read it)

Celera (CRA) will soon reveal the sequence of the genome. When completed it will steer to a new great scientific challenge. The big commercial challenge after the completion of the genome will be to understand the function of the genes identified. (This market will be colossal) Aurora stands at the crossroads of this challenge by conducting the gene discovery while at the same time assigning function information to the genes.

ABSC has a proprietary enabling technology, agreements with almost every major pharma co., forecast profitability, high growth, strong management team, track record of exceeding earnings forecast, growth industry, small float leading to great price elasticity, and one positive press release after another and most importantly an explosive market. The future of this company is very bright. This sector is very volatile, this is a long term hold. The price hit a high of $140 a few months and has now dropped to $31 7/8. The reason for the drop was due to President Clinton's comments concerning the Human Genome. Those comments do not affect ABSC, but because the shareholders did not know what Aurora Biosciences does they sold when Clinton said something negative about genomics. He said that when the Human Genome was decoded it would have to be shared. ABSC benefits fro

Some common words found in the essay are:
It's GenomeScreenTM, Celera CRA, Summary ABSC, Warner-Lambert Disclaimer, Aurora Biosciences, Growth ABSC, Molecular Biology, Growth Revenue, Human Genome, ABSC April, drug discovery, human genome, aurora biosciences, financial advisor, completion genome, set chromosomes, base pairs, discovery programs, future growth, genetic information,
Approximate Word count = 1068
Approximate Pages = 4 (250 words per page double spaced)